Our Portfolio

ReST is focused on preventing PTSD consolidation as a primary indication with several other programs in development, focused on neurodegenerative diseases and neuropsychiatric disorders, based on its targeted & selective NMDAR channel inhibition platform.

About RST-01

RST-01 is a novel and proprietary chemical entity specifically targeting certain NMDA receptor subtypes involved in synaptic plasticity. It facilitates stress extinction and neuroprotection without triggering the adverse side effects classically encountered with less selective NMDA targeting drugs.  RST-01 restores the memorization process when taken following a traumatic event.  We are on track to submit to submit our IND Application in Q3 2024

Scientific Documentation

Patents

    • 2013 – EP3003399 – novel chemical compounds derived from normemantine and use of same in the medical field​

    • 2017 – EP3723742 – use of fluoroethylnormemantine for the prevention and treatment of anxiety

    • 2020 – WO2021234324 – compound and composition for inducing neuroprotection​

    • 2021 – WO2023079187 – new synergistic combinations based on fenm and an acetylcholinesterase inhibitor

    • 2020 – EP3968977 – compositions and methods against stress-induced affective disorders and their associated symptoms

Publications

FENM as a Biomarker

    • Anne-Sophie Salabert et al.; Radiolabeling of [18F]-fluoroethylnormemantine and initial in vivo evaluation of this innovative PET tracer for imaging the PCP sites of NMDA receptors; Nuclear Medicine and Biology (2015)​

    • Anne-Sophie Salabert et al.; Evaluation of [18F]FNM biodistribution and dosimetry based on whole-body PET imaging of rats; Nuclear Medicine and Biology (2018)​

    • Marie Beaurain et al.; Pharmacological Characterization of [18F]-FNM and Evaluation of NMDA Receptors Activation in a Rat Brain Injury Model; Mol Imaging Biol. (2023)

FENM as a Drug candidate

    • Simon Couly et al.; Anti-amnesic and neuroprotective effects of Fluoroethylnormemantine in a pharmacological mouse model of Alzheimer’s disease; International Journal of Neuropsychopharmacology (2020)
    • Fluoroethylnormemantine, A novel derivative of memantine, facilitates extinction learning without sensorimotor deficits Briana K. Chen et al., International Journal of Neuropsychopharmacology (2021)
    • Fluoroethylnormemantine, a Novel NMDA Receptor Antagonist, for the Prevention and Treatment of Stress-Induced Maladaptive Behavior. Briana K.Chen et al., Biological Psychiatry (2021)
    • Freyssin A, Carles A, Guehairia S, Rubinstenn G, Maurice T. Fluoroethylnormemantine (FENM) shows synergistic protection in combination with a sigma-1 receptor agonist in a mouse model of Alzheimer’s disease. Neuropharmacology (2023)​